Enoki Mushroom Extract Halts Tumor Growth in Mice by Over 99%
Enoki Mushroom Extract Halts Tumor Growth in Mice by Over 99%
Ten‑day oral dosing shrank cancers and boosted immune cells, sparking hope and caution.
Researchers watched tumors disappear in lab mice after a short course of enoki mushroom extract, a result announced in a 2026 BMC Biotechnology paper.
The study gave mice 200 mg per kilogram of body weight each day for ten days. Within a week, tumor size stopped climbing. By the end of the ten‑day window, 66.7 % of the treated mice showed no detectable tumor at all.
In the same experiment, the untreated group kept growing tumors, confirming that the effect came from the mushroom preparation.
The extract also sparked a 166 % jump in macrophage numbers, cells that can gobble cancer cells.
“Tumors completely regressed in 67% of mice following just 10 days of oral treatment,” the authors wrote, highlighting the dramatic reversal.
Beyond shrinking tumors, the researchers measured immune‑system chemicals. Tumor‑necrosis‑factor‑alpha rose by 284 %, nitric‑oxide by 71 %, and hydrogen peroxide by 55 % compared with controls. These shifts hint that the extract may re‑program immune cells to attack cancer more aggressively.
Safety checks looked reassuring. Microscopic scans of spleen and lymph‑node tissue showed no damage in treated mice, while untreated, tumor‑bearing mice displayed spots of splenic necrosis.
Why This Matters
Mushrooms have long been studied for bioactive compounds. Polysaccharides, beta‑glucans, and other molecules in fungi can modulate immunity. The enoki (Flammulina filiformis) belongs to a group of edible mushrooms already prized for antioxidants. This new data adds a potent anticancer signal to that roster.
Most pre‑clinical cancer work relies on injections, which bypass the gut. An oral regimen that works at all is rare and could simplify future drug development. If a compound survives the digestive tract and reaches tumors intact, it may be easier to turn into a pill for patients.
However, the mouse model used, Ehrlich solid carcinoma, represents a fast‑growing, transplantable tumor. Such models often overstate efficacy compared with cancers that develop slowly in humans. The study also noted that the extract did not eradicate large, established tumors, only early‑stage growth.
Regulatory agencies will demand replication in multiple animal models and detailed toxicology before any human trial can begin. The leap from a mouse gut to a human patient is huge, and many promising pre‑clinical hits never make it past Phase I.
Historical Context
Research on mushroom‑derived anticancer agents dates back decades. Trials with lentinan from shiitake and polysaccharide‑K from turkey tail have shown modest benefits in adjunct cancer therapy. Those successes paved the way for broader interest in fungal metabolites.
Enoki mushrooms are cultivated worldwide, especially in East Asia, and are a staple in soups and salads. Their low cost and established food safety profile could lower barriers if a therapeutic version emerges.
SponsoredFor readers interested in exploring current offers on food-related products and other savings, Stack Showroom gathers every deal previously featured by The Stack in one place.
Cautious Optimism
While the numbers are striking—99.79 % tumor‑growth inhibition and two‑thirds of mice tumor‑free, the scientific community will watch for follow‑up studies. Independent labs need to reproduce the findings, and dose‑response curves must be mapped.
Even if human trials eventually succeed, the extract may end up as a complementary therapy rather than a standalone cure. Combining it with chemotherapy or immunotherapy could enhance outcomes, but interactions must be mapped carefully.
What Happens Next
- on or before December 31, 2026 — Researchers plan a second mouse study using a different cancer type to test the breadth of the effect.
- on or before December 31, 2027 — A toxicology package is slated for submission to regulatory bodies, a prerequisite for any human trial.
Comments